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epithelial sodium channel; mineralocorticoid receptor THE AMILORIDE-SENSITIVE EPITHELIAL sodium channel (ENaC) is importantly involved in the control of extracellular fluid (ECF) volume and blood pressure (18) . ENaC is a heteromeric protein with three homologous subunits ␣, ␤, and ␥ENaC (10), which facilitate sodium transport across the apical plasma membrane in the late distal convoluted tubule, connecting tubule (CNT), and collecting duct (1, 21, 39) .
Regulation of ENaC activity is complex and includes changes in protein expression of the individual subunits, redistribution of ENaC-containing vesicles to and from the apical plasma membrane, and changes in channel open probability.
Expression of ENaC at the apical plasma membrane is required for sodium transport and the importance of this aspect of ENaC regulation is illustrated by Liddle's syndrome. In this familial autosomal dominant genetic disease, a COOH-terminal truncation of either ␤ENaC or ␥ENaC results in a loss of the PY motif required for ENaC complex removal from the apical plasma membrane producing a salt-sensitive hypertensive pseudoaldosteronism (22, 37) .
A key regulator of ENaC trafficking is the adrenocortical steroid hormone aldosterone (30) . Physiological studies have shown that aldosterone treatment to adrenalectomized rats increases amiloride-sensitive sodium reabsorption after 30 min (13) , and immunohistochemistry showed increased ENaC expression after 2 h (29) . The role of the mineralocorticoid receptor (MR) in aldosterone-mediated ENaC redistribution is not clear. We have shown that blockade of the MR by spironolactone did not prevent the increased apical ENaC expression induced by dietary sodium restriction. Recently, it was suggested that aldosterone-mediated glucocorticoid receptor (GR) activation may be involved in ENaC regulation (16) , which could explain the lack of effect of spironolactone.
To further study the aldosterone-mediated regulation of ENaC redistribution, we directly investigated the effect of MR and GR blockade in chronically aldosterone-infused rats on controlled dietary sodium and water intake. This protocol provides a direct test for effects of MR and GR blockade on protein expression and trafficking of ENaC in the CNT and cortical collecting duct (CCD), in addition to effects on other key sodium transporter proteins.
METHODS
Animal protocol: aldosterone infusion rate. The infusion rate of aldosterone was tested in preliminary sets of male Sprague-Dawley rats (n ϭ 24, Taconic Farms, Germantown, NY). Twenty-four rats had osmotic minipumps delivering 250 g ⅐ kg body wt Ϫ1 ⅐ day Ϫ1 (n ϭ 12) or 50 g ⅐ kg body wt Ϫ1 ⅐ day Ϫ1 (n ϭ 12) implanted subcutaneously. Six of the rats receiving 50 g ⅐ kg body wt Ϫ1 ⅐ day Ϫ1 aldosterone were also treated with 120 mg ⅐ kg body wt Ϫ1 ⅐ day Ϫ1 spironolactone in the food. In addition, six vehicle-treated control rats were included. All rats received daily food rations of 15 g rat food (formula code 53140000; Zeigler Bros., Gardners, PA), 30 ml tap water, and were housed individually in metabolic cages. The food contained 1.7 mmol Na ϩ ⅐ 200 g body wt Ϫ1 ⅐ day Ϫ1 and 3.8 mmol K ϩ ⅐ 200 g body wt Ϫ1 ⅐ day Ϫ1 by addition of extra NaCl and KCl. After 10 days blood was collected and the plasma aldosterone concentration was deter-mined. The infusion rate of 250 and 50 g ⅐ kg body wt Ϫ1 ⅐ day Ϫ1 resulted in a plasma aldosterone concentration of 14 Ϯ 2 and 3.6 Ϯ 0.4 nM, respectively. Spironolactone cotreatment did not change the plasma aldosterone concentration (3.2 Ϯ 0.3 vs. 3.6 Ϯ 0.4 nM, not significant), and vehicle-treated control rats had significantly lower plasma aldosterone concentrations of 0.6 Ϯ 0.1 nM. The plasma aldosterone concentrations achieved by 50 g ⅐ kg body wt Ϫ1 ⅐ day
Ϫ1
are similar to the high physiological plasma concentration during chronic dietary sodium restriction (30) and were therefore used in animal protocols 1, 2, and 3. Animal protocols 1 and 2: chronic aldosterone infusion and MR antagonist (spironolactone) treatment. We carried out two studies, an initial study (protocol 1, n ϭ 14) and a confirmatory study (protocol 2, n ϭ 12). Male Sprague-Dawley rats (190 -210 g body wt, Taconic, Skensved, Denmark) were kept individually in metabolic cages. The rats received daily food rations of 15 g rat chow and 30 ml tap water. The food used in protocol 1 (Altromin 1320, Chr. Petersen A/S, Ringsted) was different from the food used in protocol 2 (formula code 53140000; Zeigler Bros.); however, the daily sodium intake in both studies was adjusted to 1.7 mmol Na ϩ ⅐ 200 g body wt Ϫ1 ⅐ day
and the daily potassium intake was adjusted to 3.8 mmol K ϩ ⅐ 200 g body wt Ϫ1 ⅐ day Ϫ1 by addition of extra NaCl and KCl. All rats ate all of the food given. During the entire experiment, there was a 12:12-h artificial light-dark cycle, a temperature of 21 Ϯ 2°C, and humidity of 55 Ϯ 2%.
After 3 days of equilibration, rats had osmotic minipumps (model 2002; Alzet, Palo Alto, CA) implanted subcutaneously under 3.5% halothane anesthesia (Halocarbon Laboratories), while bupivacaine was injected subcutaneously for pain relief. The osmotic minipumps delivered 50 g ⅐ kg body wt Ϫ1 ⅐ day Ϫ1 aldosterone (Sigma A6628) dissolved in DMSO (25% vol/vol) and sterile saline (75% vol/vol). The control rats received pumps with vehicle only. Rats also treated with spironolactone in addition to aldosterone infusion had 120 mg ⅐ kg body wt Ϫ1 ⅐ day Ϫ1 spironolactone (Sigma 3378) added to the food. This spironolactone dose is markedly higher than what has previously been shown to block the MR more than 95% (12) . Urine was collected daily and analyzed for concentrations of Na ϩ , K ϩ , creatinine, urea, and for the measurement of the urine osmolality.
After 7 days, the rats were anesthetized with isoflurane and a large abdominal incision was made. Two milliliters of blood were collected from the inferior vena cava and rapidly transferred into a lithiumheparin or sodium-EDTA-coated tube (Vacuette, Greiner bio-one, Austria). Next, the right kidney was rapidly removed and dissected into three regions: 1) cortex and outer stripe of outer medulla, 2) inner strip of the outer medulla, and 3) inner medulla, for immunoblotting as described under semiquantitative immunoblotting.
Immediately after removal of the right kidney a large perfusion needle was inserted in the abdominal aorta from the aortic bifurcation. The inferior vena cava was immediately cut open to establish an outlet for the fixative. Blood was flushed from the kidneys with cold 0.01 M PBS (pH 7.4) for 15 s, before switching to cold 3% paraformaldehyde in 0.01 M PBS buffer (pH 7.4) for 3 min. The rat was euthanized during the process of fixation by the rapid bleeding. The kidney was removed, and the midregion was sectioned into 2-to 3-mm transverse sections and immersion fixed for additionally 1 h, followed by 3 ϫ 10-min washes with 0.1 M PBS buffer, pH 7.4. Further processing is described in Immunohistochemistry.
Animal protocol 3: chronic aldosterone infusion and combined MR antagonist (spironolactone) and GR antagonist (RU486) treatment. We used 24 male Sprague-Dawley rats (190 -210 g body wt; Taconic) that were housed and fed as described in the animal protocol for protocol 1. After equilibration in cages, osmotic minipumps delivering aldosterone were implanted in 18 rats as described in animal protocol for protocol 1. Six rats received only aldosterone infusion. Six aldosterone-infused rats were cotreated with 15 mg ⅐ kg body wt Ϫ1 ⅐ day Ϫ1 RU486 (Sigma M8046) in the food. This dose of RU486 has previously been shown to effectively block muscle proteolysis induced by 200 mg ⅐ kg body wt Ϫ1 ⅐ day Ϫ1 corticosterone (44) . Six aldosterone-infused rats we cotreated with both 15 mg ⅐ kg body wt Ϫ1 ⅐ day Ϫ1 RU486 and 120 mg ⅐ kg body wt Ϫ1 ⅐ day Ϫ1 spironolactone in the food. Six rats were untreated control rats (no aldosterone infusion). Urine was collected daily and analyzed for concentrations of Na ϩ , K ϩ , creatinine, urea and for the measurement of the urine osmolality. After 7 days of treatment, the rats were euthanized as described for protocol 1 and 2.
Approval of animal protocols. Semiquantitative immunoblotting. The dissected renal cortex, inner stripe of the outer medulla (ISOM), and inner medulla were homogenized in isolation solution containing 0.3 M sucrose, 25 mM imidazole, 1 mM EDTA, 8.5 M leupeptin, 1 mM phenylmethylsulfonyl fluoride, pH 7.2. Homogenates were centrifuged at 4,000 g for 15 min at 4°C to remove cellular debris. Supernatant protein was solubilized at 65°C for 15 min in Laemmli sample buffer. To confirm equal loading of protein, an initial gel was stained with Coomassie Blue dye as described previously (40) . SDS-PAGE was performed on 9 or 12% polyacrylamide gels, and proteins were transferred electrophoretically (Bio-Rad Mini Protean II) to nitrocellulose membranes (Hybond ECL RPN3032D, Amersham Pharmacia Biotech, Little Chalfont, UK). Membranes were blocked with 5% milk in PBS-T (80 mM Na2HPO4, 20 mM NaH2PO4, 100 mM NaCl, 0.1% Tween 20, pH 7.5) for 1 h and incubated overnight at 4°C with primary antibodies. The sites of antibody-antigen reaction were visualized with horseradish peroxidase (HRP)-conjugated secondary antibodies (P447 or P448, diluted 1:3,000; DAKO, Glostrup, Denmark) with an enhanced chemiluminescence (ECL or ECLϩplus) system and exposure to photographic film (Hyperfilm ECL, RPN3103K, Amersham Pharmacia Biotech). The band densities were quantified by computer scanning of films and normalizing the densitometry values to facilitate comparisons. We used Scion Image (Scion, Frederick, MD) for computer analysis of band pixel intensities. Results are listed as the relative band densities between the groups and not absolute, hence the term semiquantitative immunoblotting.
Immunohistochemistry. Kidneys were perfusion fixed by insertion of a 17-gauge needle in the abdominal aorta. Blood was flushed from the kidneys with cold 0.01 M PBS (pH 7.4) for 15 s, before switching to cold 3% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.4) for 3 min. The kidney was removed, and the midregion was sectioned into 2-to 3-mm transverse sections and immersion fixed for additionally 1 h, followed by 3 ϫ 10-min washes with 0.1 M cacodylate buffer, pH 7.4. The tissue was dehydrated in graded ethanol and left overnight in xylene. After tissue embedding in paraffin, 2-m sections were cut on a rotary microtome (Leica Microsystems A/S, Herlev, Denmark).
For immunolabeling, the sections were dewaxed with xylene and rehydrated with graded ethanol before endogenous peroxidase activity was blocked by 0.5% H2O2 in absolute methanol for 10 min. Sections were microwave boiled in a target retrieval solution (1 mmol/l Tris, pH 9.0, with 0.5 mM EGTA) for 10 min, before nonspecific binding was blocked with 50 mM NH 4Cl in PBS for 30 min, and 3 ϫ 10-min blocking with PBS blocking buffer (1% BSA, 0.05% saponin, and 0.2% gelatin). The sections were incubated with primary antibody (diluted in PBS with 0.1% BSA and 0.3% Triton X-100) overnight at 4°C. The sections were washed 3 ϫ 10 min with PBS wash buffer containing 0.1% BSA, 0.05% saponin, and 0.2% gelatin and incubated with HRP-conjugated secondary antibody (goat anti-rabbit immunoglobulin, DAKO P448, DAKO A/S) for 1 h at room temperature. After 3 ϫ 10-min rinses with PBS wash buffer, the sites of antibodyantigen reaction were visualized with a brown chromogen produced within 10 min by incubation with 0.05% 3,3Ј-diaminobenzidine tetrachloride (Kem-en Tek, Copenhagen, Denmark) dissolved in distilled water with 0.1% H 2O2. Mayers hematoxylin was used for counterstaining, and after dehydration coverslipes were mounted with hydrophobic medium (Eukitt, O. Kindler GmbH, Freiburg, Germany). For sections prepared for immunofluorescence, a secondary fluorescent antibody was used (goat anti-rabbit IgG, Alexa Fluor 488 11008, and goat anti-mouse IgG Alexa Fluor, 546 11003, Molecular Probes, Eugene, OR). After 1-h incubation at room temperature, coverslipes were mounted with a hydrophilic mounting media containing antifading reagent (n-propyl-gallat, P-3101, Sigma, St. Louis, MO). Light microscopy was carried out with Leica DMRE (Leica Microsystems A/S). Laser confocal microscopy was carried out on a Leica TCS-SP2 laser confocal microscope (Heidelberg, Germany).
Semiquantitative confocal laser-scanning microscopy. For semiquantitative analysis, microscope settings (light intensity, PMT offset and gain, sampling period, and averaging) were identical for all rats, and the observer was blinded for the treatment of the individual rats. From each rat five images of tubule segments were identified as DCT cells by the following criteria: tall cuboid cells, apically located nucleus, marked basolateral striation, only one cell type in tubule segment, and negative for NKCC2 labeling. Digital images were analyzed using Image-Pro Plus software (Media Cybernetics, Silver Spring, MD) to detect regions of interest and measurements of the average pixel intensities in DCT cells using semiautomated macros. The dynamic range was set such that the tissue with the most intense fluorescence signal only had few saturated pixels. The results are given as mean density.
Antibodies. Rabbit polyclonal antibodies to the following renal sodium transporters were utilized: the type 3 Na-H exchanger (NHE3) of the proximal tubule (15), the Na-K-2Cl cotransporter (NKCC2) of the thick ascending limb (27) , the thiazide-sensitive Na-Cl cotransporter (NCC) of the distal convoluted tubule (28), the ENaC subunits ␣ENaC, ␤ENaC, and ␥ENaC in the CNT and collecting duct (30, 33) , and the monoclonal ␣ 1-subunit of Na-K-ATPase in all renal tubular segments (33) . The polyclonal antisera from rabbits were affinitypurified against the immunizing peptides as previously described (27, 28) . Specificity of the antibodies has been demonstrated by showing unique peptide-ablatable bands on immunoblots and a specific labeling by immunohistochemistry.
Presentation of data and statistical analysis. Quantitative data are presented as means Ϯ SE. Data were analyzed by one-way ANOVA followed by Tukey's multiple comparisons post hoc test. Multiple comparisons tests were only applied when a significant difference was determined in the ANOVA (P Ͻ 0.05). P values Ͻ0.05 were considered statistically significant.
RESULTS
Spironolactone treatment blocks aldosterone-induced decrease in plasma potassium. Chronic infusion of aldosterone producing a plasma aldosterone concentration in the high physiological range (see METHODS) was associated with significantly decreased plasma potassium concentration compared with untreated control rats (3.1 Ϯ 0.1 vs. 4.3 Ϯ 0.2 mM, P Ͻ 0.05; Table 1 ). The decrease in plasma potassium concentration was effectively blocked and normalized to control levels by administration of spironolactone to the aldosterone-infused rats (4.0 Ϯ 0.2 vs. 4.3 Ϯ 0.2 mM, not significant; Table 1 ). The urinary excretion rates of sodium and potassium were not significantly different between groups consistent with equal dietary sodium intake and steady state. There was no evidence of changes in glomerular filtration rate, indicated by unaffected creatinine clearance. Additional physiological data are summarized in Table 1 .
Aldosterone-induced increase in the protein expression of NCC and Na-K-ATPase ␣ 1 -subunit in the kidney cortex is spironolactone sensitive. Immunoblotting using protein from the renal cortex revealed that protein expression of the Na-K-ATPase ␣ 1 -subunit, and NCC was markedly increased in the aldosterone-infused rats compared with control rats (Fig. 1) . The aldosterone-induced increases in Na-K-ATPase ␣ 1 -subunit and NCC were completely blocked by spironolactone treatment of the aldosterone-infused rats. A summary of densitometry analysis of immunoblots is shown in Table 2 . Immunohistochemical analysis of tissue sections from kidney cortex labeled for Na-K-ATPase ␣ 1 -subunit showed an increased labeling intensity of Na-K-ATPase ␣ 1 -subunit in the basolateral plasma membrane domain in the CCD ( Fig. 2A) and in the CNT (not shown) in aldosterone-infused rats compared with untreated control rats (Fig.  2C) . Treatment with spironolactone largely blocked the aldosterone-induced increase in Na-K-ATPase ␣ 1 -subunit labeling intensity in the CCD (Fig. 2B) and CNT (not shown). The expression levels of the Na-K-ATPase ␣ 1 -subunit in the DCT were examined using semiquantitative immunofluorescence confocal microscopy. To distinguish cortical thick ascending limb (cTAL) from DCT, the sections were labeled for NKCC2 (green labeling). Five images from each rat kidney were recorded for analysis. In contrast to the CCD, the results showed no significant changes in the average immunofluorescence density of the Na-K-ATPase ␣ 1 -subunit (red labeling; Fig. 2, D-F) in the DCT cells when comparing the three groups (in arbitrary units, aldosteroneinfused rats 44 Ϯ 5, aldosterone-infused rats given spironolactone 37 Ϯ 4, untreated control rats 41 Ϯ 1, not signifi- Values are means Ϯ SE. *Significantly different from control and †signif-icantly different from Aldo ϩ Spiro (P Ͻ 0.05). Aldo, aldosterone; Spiro, spironolactone; Osmol, osmolality; P, plasma; U, urine; VNaϩ, urinary sodium excretion; VKϩ, urinary potassium excretion; CCr, creatinine clearance. cant). The downregulation to control levels of Na-K-ATPase protein abundance in response to spironolactone was confirmed in a repeat study (protocol 2; Table 2 ). The repeat study also confirmed the changes in plasma potassium concentration in the aldosterone-infused rats compared with untreated control rats (3.0 Ϯ 0.1 vs. 3.9 Ϯ 0.1 mM, P Ͻ 0.05) and normalization to control levels with spironolactone treatment (3.6 Ϯ 0.1 vs. 3.9 Ϯ 0.1 mM, not significant).
Consistent with immunoblotting results, the labeling intensity of NCC in the apical plasma membrane domain of DCT cells was increased by aldosterone treatment (Fig. 2G ) compared with untreated control rats (Fig. 2H) . Spironolactone blocked the aldosterone-induced NCC upregulation completely, and these rats showed labeling intensity similar to untreated control rats (Fig. 2I) . Similar changes in immunoperoxidase labeling were found in protocol 2 (not shown). These results support that the aldosterone-induced upregulation of Na-K-ATPase ␣ 1 -subunit and NCC is mediated by activation of the classical MR and that the dose of spironolactone was sufficient to block the MR.
Aldosterone-induced apical targeting of ENaC in CNT and CCD is not blocked by spironolactone cotreatment. The purpose of this study was to determine whether aldosteroneinduced ENaC trafficking is sensitive to spironolactone blockade of the MR. To study this, we labeled tissue sections of kidney cortex with antibodies specific for the ␣ENaC or ␥ENaC subunits. The intensity of ␣ENaC immunoperoxidase labeling was stronger in the CNT and CCD of aldosteroneinfused rats compared with untreated control rats (Fig. 3, A and  D vs. C and F) . The distribution of ␣ENaC labeling in aldosterone-infused rats was mainly localized to the apical cell domain and plasma membrane. In contrast, labeling in untreated control rats was mainly present in the cytoplasm with less intense labeling of the apical plasma membrane domain. Cotreatment with spironolactone to the aldosterone-infused rats did not alter the ␣ENaC immunolabeling pattern in CNT and CCD (Fig. 3, B and E) compared with aldosterone-infused rats (Fig. 3, A and D) . The ␣ENaC labeling was strong and predominantly seen in the apical cell domain and plasma membrane (Fig. 3, B and E) compared with untreated control rats. Tissue sections labeled with ␥ENaC antibodies also showed increased apical targeting in aldosterone-infused rats and in the aldosterone-infused rats cotreated with spironolactone compared with untreated control rats (Fig. 4) . However, the overall labeling intensity was unchanged between the groups (Fig. 4) . ␤ENaC showed changes similar to ␥ENaC (not shown). The lack of effect of spironolactone on aldosteroneinduced ENaC trafficking was confirmed in protocol 2 (images not shown). These results suggest that aldosterone-mediated trafficking of ENaC (␣-, ␤-, and ␥-subunits complex) is spi- Values are means Ϯ SE. *Significantly different (P Ͻ 0.05) from control and †significantly different (P Ͻ 0.05) from Aldo ϩ Spiro (P Ͻ 0.05). Fig. 1 . Semiquantitative immunoblotting of protein prepared from the kidney cortex in protocol 1. The Na-K-ATPase ␣1-subunit appears as a single ϳ95-kDa band (A). NCC appears as a broader 165-kDa band (B). Densitometry analysis revealed that the Na-K-ATPase ␣1-subunit and NCC are significantly increased by aldosterone treatment compared with control and normalized to control levels by spironolactone. *P Ͻ 0.05 compared with untreated control rats. #P Ͻ 0.05 compared with spironolactone-treated, aldosteroneinfused rats. ronolactone insensitive and thus not mediated via activation of the classical MR.
Aldosterone-induced ENaC trafficking is insensitive to combined blockade of MR and GR.
In addition to the activation of MR, elevated plasma aldosterone concentrations may also activate the GR and thereby regulate ENaC activity (16) . To determine whether GR activation could play a role in the spironolactone-insensitive ENaC trafficking, we examined the effect of RU486, a GR antagonist, in aldosteroneinfused rats cotreated with spironolactone (protocol 3). Fig. 3 . Immunoperoxidase microscopy of the ␣ENaC subunit in the kidney cortex in protocol 1. In the aldosterone-infused rats, the immunolabeling was strong in the apical cell domain and there was distinct labeling of the apical plasma membrane domain (arrow) in connecting tubule cells of the CNT (A) and principal cells of the CCD (D). In rats treated with both aldosterone infusion and oral spironolactone (B and E), the labeling intensity and labeling distribution were similar to the rats treated only with aldosterone. In the untreated control rats, the labeling intensity was reduced and mainly dispersed in the cytoplasm (arrowhead) with no distinct labeling of the apical plasma membrane domain (C and F). Scalebar ϭ 10 m (A-C) and 20 m (D-F). Fig. 2 . Immunoperoxidase microscopy and immunofluorescence confocal microscopy of Na-K-ATPase ␣1-subunit and NCC in the kidney cortex in protocol 1. Na-K-ATPase ␣1-subunit labeling is seen in the basolateral cell domain (arrows) in the cortical collecting duct (CCD) and is markedly increased in the aldosterone-infused rats (A) compared with rats receiving spironolactone (B) and untreated control rats (C), which appeared similar. To identify distal convoluted tubule (*), we used immunofluorescence double labeling with Na-K-ATPase ␣1-subunit (red) and NKCC2 (green), which identifies cTAL. In NKCC2 negative tubule segments with distal convoluted tubule (DCT) morphology, there was no overall difference in the labeling intensity, although the labeling in aldosterone-treated rats appeared marginally stronger (D) and in spironolactone-treated rats marginally weaker (E) compared with untreated control rats (F). NCC is expressed in the apical plasma membrane (arrows) of the DCT and is increased in the aldosterone-infused rats (G). The increased labeling was blocked by spironolactone to the level of untreated control rats (H and I). Scalebar ϭ 10 m (A-C and G-I) and 50 m (D-F).
Immunoperoxidase labeling with ␤ENaC and ␥ENaC antibodies showed apical targeting in the CNT and CCD in aldosterone-infused rats (Fig. 5, A and E) , as observed in protocol 1 (Figs. 3 and 4) . Cotreatment of aldosteroneinfused rats with RU486 alone (Fig. 5, B and F ) or in combination with spironolactone (Fig. 5 , C and G) had no effect on aldosterone-induced ENaC trafficking to the apical plasma membrane and ENaC labeling in CNT and CCD. In contrast, untreated control rats showed dispersed labeling without apical targeting (Fig. 5, D and H) . The plasma potassium was decreased in aldosterone-infused rats and aldosterone-infused rats cotreated with RU486 but normalized to control levels by addition of spironolactone (Table   3 ). Additional physiological data are summarized in Table 3 .
Spironolactone did not block ␣ENaC upregulation in aldosterone-treated rats. It has previously been shown that aldosterone treatment increases ␣ENaC protein abundance (30) . Immunoblotting against the ENaC subunits using protein prepared from kidney cortex in both protocol 1 and protocol 2 confirmed increased protein expression of ␣ENaC (Fig. 6 and Table 2) . Surprisingly, aldosterone-infused rats cotreated with spironolactone did not decrease the protein abundance of ␣ENaC compared with rats treated only with aldosterone ( Fig.  6 and Table 2 ). Moreover, cotreatment with both spironolactone and RU486 in aldosterone-infused rats (protocol 3) also Fig. 4 . Immunoperoxidase microscopy of the ␥ENaC subunit in the kidney cortex in protocol 1. In the aldosterone-infused rats, the immunolabeling is concentrated towards the apical plasma membrane domain (arrows) in connecting tubule cells of the CNT (A) and principal cells of the CCD (D). In aldosterone-infused rats receiving spironolactone (B and E), the labeling remained in the apical plasma membrane domain. In the untreated control rats (E and F), the labeling intensity was similar to the treated groups, but the labeling was mainly dispersed in the cytoplasm (arrowheads). did not block the increased ␣ENaC protein expression compared with untreated control (Fig. 7A and Table 4 ), despite normalization of the plasma potassium concentration ( Table 3 ). The protein expression of ␣ENaC in aldosterone-infused rats cotreated with RU486 alone was similar to aldosterone-infused rats and significantly elevated compared with untreated control rats ( Table 4) .
The mechanism mediating the elevated ␣ENaC protein abundance in the presence of MR and GR blockade is unclear. It may be speculated that MR blockade may lead to increased ANG II levels that, in turn, could upregulate ␣ENaC protein expression directly (6, 9) . Measurements of plasma ANG II in protocol 3 showed more than a 10-fold increase in ANG II in aldosterone-infused rats cotreated with spironolactone and RU486 compared with aldosterone-infused rats and aldosterone-infused rats cotreated with RU486 (Table 4) . ANG II was not significantly lower in aldosterone-infused rats and aldosterone-infused rats cotreated with RU486 compared with untreated control rats. Measurement of plasma aldosterone concentration in the same animals showed significantly elevated plasma aldosterone in all aldosterone-infused rats compared with untreated controls but no significant difference between the groups of aldosterone-infused rats (Table 3) .
Aldosterone is also known to cause a molecular weight shift of ␥ENaC from an 85-kDa band to a 70-kDa band (30) which we confirmed (Fig. 6C and Tables 2 and 4) . The shift in molecular mass from 85 to 70 kDa was not reversed by cotreatment with spironolactone (protocol 1; Fig. 6C and Table  2 ) or cotreatment with both spironolactone and RU486 (protocol 3; Fig. 7C and Table 4 ). Interestingly, aldosteroneinfused rats treated with RU486 alone showed a significantly decreased total abundance of ␥ENaC compared with control rats and compared with the other aldosterone-infused groups (Table 4) . For unknown reasons, the immunoblot for ␥ENaC in protocol 2 showed only a weak and unchanged 70-kDa form of ␥ENaC ( Table 2 ). The protein abundance of ␤ENaC was unchanged in all studies (Figs. 6B and 7B; Tables 2 and 4) .
In addition to the findings for ENaC subunits, NCC and Na-K-ATPase ␣ 1 -subunit, there was no change in the protein expression of the sodium transporter NHE3 expressed in the proximal tubule and thick ascending limb of Henle, and of NKCC2 expressed in the thick ascending limb in either protocol 1 (Fig. 8 and Table 2 ) or protocol 2 ( Table 2 , blots not shown).
DISCUSSION
We investigated the effects of MR and GR blockade on the regulation of ENaC trafficking in aldosterone-infused rats. ENaC trafficking to the apical plasma membrane in CNT and CCD of aldosterone-infused rats could not be blocked by cotreatment with MR and GR antagonists. Thus we provide evidence for ENaC trafficking mediated by a mechanism independent of the classical MR and GR in rats receiving aldosterone infusion. In contrast, we showed that aldosterone upregulates the protein expression of NCC and Na-K-ATPase ␣ 1 -subunit in kidney cortex through MR activation, consistent with previous studies. These results extend our previous findings of spironolactone-insensitive ENaC trafficking induced by dietary sodium restriction (33) .
Regulation of ECF volume, NCC, and Na-K-ATPase. In the present study, we investigated the direct effect of aldosterone on ENaC trafficking. Aldosterone infusion constitutes a physiological state prone to expansion of the ECF volume and hypertension that could be mediated by the regulation of aldosterone-sensitive renal sodium transporters and channels (e.g., NCC, Na-K-ATPase, and ENaC). However, it was previously shown that 2 wk of aldosterone infusion at a similar dose combined with saline drinking water did not cause weight gain or hypertension (34) . The plasma aldosterone concentration in the high physiological range, combined with a normal daily sodium intake used in the present study, is therefore not expected to lead to massive ECF volume expansion, weight gain, or hypertension.
It should also be noted that the model used in this study is not an aldosterone escape model. During aldosterone escape, the kidney increases urinary sodium excretion despite elevated plasma aldosterone concentration when sodium intake is increased, preventing excessive fluid retention and blood pressure increase. Aldosterone escape is associated with a selective downregulation of NCC in aldosterone-infused rats when the daily sodium intake increased from 0.02 to 2 mmol Na ϩ /day (43) . It should be emphasized, however, that the protein abundance of NCC in the aldosterone-infused rats on a 2-mmol Na intake per day did increase compared with control rats as shown here and previously (28) .
In this study, we show that the aldosterone-induced regulation of NCC is sensitive to blockade by spironolactone, which normalizes the expression level to control levels. This effect of Values are means Ϯ SE. *Significantly different (P Ͻ 0.05) from control and †significantly different (P Ͻ 0.05) from Aldo ϩ Spiro ϩ RU. 1 For ANG II measurements; n ϭ 5 in Aldo and control and n ϭ 4 in Aldo ϩ Spiro ϩ RU and Aldo ϩ RU. RU, RU486; BW, body weight. Fig. 6 . Semiquantitative immunoblotting of protein prepared from the kidney cortex in protocol 1. ␣ENaC (A) and ␤ENaC (B) appears as single ϳ85-kDa bands. ␥ENaC (C) appears as an upper 85-kDa band and a lower 70-kDa band, thought to be a proteolytic cleavage product of the 85-kDa band. Densitometry analysis revealed that ␣ENaC was significantly increased in aldosterone-treated rats and rats treated with both and aldosterone spironolactone. The total ␥ENaC was unchanged, although there was an increased expression of the 70-kDa band of ␥ENaC. ␤ENaC was unchanged. *P Ͻ 0.05 compared with untreated control rats. Fig. 7 . Semiquantitative immunoblotting of protein prepared from the kidney cortex in protocol 3. ␣ENaC (A) was upregulated in all aldosterone-infused groups compared with control. ␤ENaC (B) was unchanged. The 85-kDa form of ␥ENaC (C) was downregulated in all aldosterone-infused groups while the lower 75-kDa band was increased. *P Ͻ 0.05 compared with untreated control rats.
spironolactone is consistent with previous observations in sodium-restricted rats (33) and supports the view that NCC is regulated by MR activation. Interestingly, it was recently shown that low-sodium intake is associated with redistribution of NCC in subapical vesicles to the apical plasma membrane (35) . In our study, we are not able to determine whether the immunoperoxidase labeling of NCC is located in the apical plasma membrane or a subapical vesicle pool.
The Na-K-ATPase is also a well-known aldosterone target. Previously, aldosterone has been shown to increase the Na-KATPase activity in the CNT and CCD but not in the DCT (17), while adrenalectomized rats showed a 50% reduction in the Na-K-ATPase ␣ 1 mRNA expression in the CCD (14, 42) . Consistent with this, we showed a markedly increased protein expression of the Na-K-ATPase ␣ 1 -subunit in the kidney cortex in response to aldosterone, which was blocked by spironolactone. Moreover, immunohistochemistry revealed that the changes in Na-K-ATPase ␣ 1 -subunit expression occurred in the CCD and CNT, while no changes were observed in the DCT. Our results support the previous studies showing changes in Na-K-ATPase activity and mRNA expression with changes in aldosterone levels (14, 17, 42) . Interestingly, our findings are not consistent with the observations from the 8-day-old MR knockout mice, which showed no change in Na-K-ATPase ␣ 1 -subunit mRNA (5), suggesting that the regulation of the Na-K-ATPase ␣ 1 is complex.
Finally, an important premise for the conclusion of the present study is the efficacy of the MR blockade by spironolactone. In addition to the complete blockade of the aldosterone-induced upregulation of NCC and Na-K-ATPase ␣ 1 -subunit, the efficacy of MR blockade by spironolactone was confirmed in all three studies by a complete blockade of the aldosterone-mediated decrease in plasma potassium concentration.
ENaC trafficking in aldosterone-infused rats was insensitive to blockade of the MR and GR. It is well documented that aldosterone induces ENaC trafficking and increased ENaC activity at the apical plasma membrane (2, 4, 29) . The MR is commonly thought to be involved in ENaC trafficking in vivo, although effects of MR antagonism on aldosterone-induced ENaC trafficking have not previously been studied. We previously showed that ENaC trafficking induced by dietary sodium restriction could not be blocked by spironolactone (33) . In a novel CCD cell line (mCCD cll ) increased ENaC activity induced by aldosterone could be blocked by spironolactone, but the effect of spironolactone on aldosterone-induced ENaC trafficking was not directly examined (16) . Since ENaC is regulated both by changes in open probability and trafficking, it is possible that spironolactone may affect the open probability but not ENaC trafficking. Decreased ENaC activity during spironolactone treatment is consistent with the potassium sparing effect of spironolactone and the changes on plasma potassium observed in the present study. The role of the MR in ENaC trafficking in vivo therefore remains unclear. Aldosterone has a lower affinity for the GR compared with the MR (K d ϭ 14 nmol/l vs. K d ϭ 0.5 nmol/l) (24) . It has been suggested that aldosterone binding to the GR may play an (3, 11, 29, 32) . SGK regulates ENaC through phosphorylation of the ubiquitin ligase Nedd4 -2 and thereby decreases the ability of Nedd4 -2 to bind and ubiquitylate ENaC, promoting longer retention of ENaC in the apical plasma membrane (38) . Alternatively, the increased ANG II concentration in the spironolactone-treated rats could potentially explain the spironolactone-insensitive ENaC trafficking, although ANG II has not previously been associated with ENaC trafficking. ANG II induces a rise in intracellular IP3 and DAG leading to increased Ca 2ϩ and PKC activation (8, 26 ) that, in turn, could regulate SGK and thus ENaC trafficking.
Protein expression of ␣ENaC and the 70-kDa ␥ENaC form was not decreased by spironolactone treatment. In our previous study, increased ␣ENaC expression due to dietary sodium restriction could be blocked by spironolactone treatment (33) . In this study, we observed no effect of spironolactone on the increased ␣ENaC protein abundance in aldosterone-infused rats. One possible explanation for this difference could be the markedly increased plasma concentration of ANG II in the aldosterone-infused rats treated with spironolactone and RU486 compared with rats given either aldosterone infusion or RU486. ANG II has been shown to directly increase ␣ENaC mRNA and protein expression through the AT 1a receptor (6, 9) . Blockade of the AT 1a receptor with candesartan in the presence of high-dose spironolactone was associated with decreased ␣ENaC mRNA and protein expression (6) . Moreover, the AT 1a receptor knockout mice, which showed elevated plasma aldosterone, had markedly decreased ␣ENaC protein expression. Thus spironolactone treatment may lead to a compensatory increase in ␣ENaC expression mediated by increased ANG II masking the effect of spironolactone. In contrast, the ANG II levels in both sodium-restricted rats and sodium-restricted rats receiving spironolactone are expected to be markedly elevated and will therefore not differentially affect the ␣ENaC protein expression.
In two of the three protocols, we found no evidence that spironolactone could reverse the aldosterone-induced molecular mass shift of ␥ENaC from 85 to 70 kDa. The lack of effect of spironolactone is in contrast to what was observed during sodium restriction (33) . The molecular mass shift of ␥ENaC associated with increased aldosterone (30) is thought to be the result of proteolytic cleavage by membrane-associated serine proteases (41) . However, ENaC cleavage also occurs as a part of maturation in the Golgi apparatus by the protease furin (25) . Common for both pathways of cleavage is that the regulatory mechanism remains unknown and we therefore cannot explain the lack of effect of spironolactone. It should, however, be emphasized that spironolactone treatment was associated with physiological renal changes (including plasma potassium) as well as blocking the aldosterone-induced increases in NCC and ␣ 1 -subunit of the Na-K-ATPase expression, consistent with previous evidence documenting its effect. Based on this, it is speculated that the differences seen in this study compared with previous studies in relation to ␣ENaC expression and ␥ENaC proteolytic cleavage may be caused by different experimental conditions between sodium restriction and direct aldosterone infusion.
In summary, the present study provides new evidence of ENaC trafficking in aldosterone-infused rats independent of activation of the MR and GR. Furthermore, the study demonstrated an aldosterone-induced increase in NCC expression in the DCT and Na-K-ATPase ␣ 1 expression in CNT and CCD mediated by the classical MR.
